Article Sidebar

PDF
Date Published: 18/10/2021
Abstract Views: 699
Views PDF: 252
DOI: https://doi.org/10.51298/vmj.v506i1.1178
Issue
Vol. 506 No. 1 (2021)
Section
Các bài báo
How to Cite
Thị Hà, N. ., & Lê Huy, T. . (2021). RESULTS OF NEOADJUVANT CONCURRENT CHEMORADIOTHERAPY IN STAGE II-III MIDDLE-LOWER THIRD ESOPHAGEAL CANCER AT 108 CENTRAL MILITARY HOSPITAL. Vietnam Medical Journal, 506(1). https://doi.org/10.51298/vmj.v506i1.1178

RESULTS OF NEOADJUVANT CONCURRENT CHEMORADIOTHERAPY IN STAGE II-III MIDDLE-LOWER THIRD ESOPHAGEAL CANCER AT 108 CENTRAL MILITARY HOSPITAL

Nguyễn Thị Hà1, Trịnh Lê Huy2,
1 108 Military Central Hospital
2 Department of Oncology, Hanoi Medical University

Main Article Content

Abstract

Objectives:To assess the treatment results of neoadjuvant chemoradiation in the middle and lower thirds, stage II, III esophageal cancer patients at the 108 Military Central Hospital. Subject and method:A retrospective and prospective descriptive study with 44 stage II-III esophageal cancer patientsunderwent preoperative, concurrent chemotherapy with paclitaxel/carboplatin and radiation with a dose of41.4Gy/23fx followed by surgery. Results: The means age was 55 years old, the percentage of malewas 97,7%. The dysphagia rate was 81,8, weight loss was found in 27/44 (61,2%), the mean length of tumor is 6 ±0.25 cm. The subclinical complete responses were 38.6%. The pathology complete response was 43.2% (pT0N0) and R0 resection was achieved for 41 patients (93.2%). Side effects fatigue, esophageal mucositis, and leukopenia, most of which were in grade 1-2.Conclusions:Preoperative chemoradiation in an effective treatment for stgage II-III esophageal cancer patients with acceptable side effects, complications, and surgical complications.

Article Details

Keywords

Esophageal cancer, preoperative chemoradiotherapy

References

1. Sung H., Ferlay J., Siegel R.L. và cộng sự. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 71(3), 209–249.
2. (2017). Common Terminology Criteria for Adverse Events (CTCAE). 155.
3. Phạm Đức Huấn (2003), Nghiên cứu điều trị phẫu thuật ung thư thực quản, Luận án tiến sĩ y học, Trường Đại học Y Hà Nội.
4. Nguyễn Đức Lợi (2015), Đánh giá hiệu quả phác đồ hoá xạ trị đồng thời và một số yếu tố tiên lượng ung thư biểu mô vẩy thực quản giai đoạn III,IV, Luận án tiến sĩ y học, Trường Đại học Y Hà Nội.
5. van Hagen P., Hulshof M.C.C.M., van Lanschot J.J.B. và cộng sự. (2012). Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer. N Engl J Med, 366(22), 2074–2084.
6. Cook M.B., Kamangar F., Whiteman D.C. và cộng sự. (2010). Cigarette smoking and adenocarcinomas of the esophagus and esophagogastric junction: a pooled analysis from the international BEACON consortium. J Natl Cancer Inst, 102(17), 1344–1353.
7. Nguyễn Xuân Hòa (2018), Nghiên cứu úng dụng phẫu thuật nội soi cắt thực quản và nạo vét hạch rộng hai vùng (ngực- bụng) trong điều trị ung thư thực quản., Luận án tiến sĩ y học, Trường Đại học Y Hà Nội, Hà Nội.
8. Choy H. (2000). Combining taxanes with radiation for solid tumors. Int J Cancer, 90(3), 113–127.
9. van Meerten E., Muller K., Tilanus H.W. và cộng sự. (2006). Neoadjuvant concurrent chemoradiation with weekly paclitaxel and carboplatin for patients with oesophageal cancer: a phase II study. Br J Cancer, 94(10), 1389–1394.